Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran Bioavailability with Rifampicin
NCT02173717Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2009
- Primary completion
- Jul 2009
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of dabigatran in thromboembolism, sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve over the time interval from 0 extrapolated to infinity (AUC0-inf) of total dabigatran at Day 23 and Maximum measured concentration (Cmax) of total dabigatran at Day 23. Started Jun 2009; status: completed.
02
Drugs
dabigatran
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02173717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02173717.